SCHEMBL17350123

SCHEMBL17350123

CC(C)c1cccc(Oc2ncc(NC(=O)[C@@H](C)NC(=O)O)cn2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.41
BRAF P15056 1/20 0.41
ACACB O00763 1/20 0.40
PTGS1 P23219 1/20 0.40
CASP1 P29466 1/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
FFAR1 O14842 1/20 0.39
NPY5R Q15761 1/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
MTNR1B P49286 1/20 0.38
TSHR P16473 1/20 0.38
CDK8 P49336 1/20 0.38
KDR P35968 1/20 0.37
TEK Q02763 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13832422 0.86 JAK2 (0.41) RORCBRAFCASP1KMT2AMEN1
SCHEMBL13268378 0.86 RORC (0.40) RORCBRAFACACBKMT2AMEN1
SCHEMBL1982041 0.85 XIAP (0.44) RORCBRAFPTGS1CASP1KMT2A
SCHEMBL21980919 0.80 CASP1 (0.41) RORCBRAFACACBPTGS1CASP1
SCHEMBL13720514 0.80 CASP1 (0.41) RORCBRAFACACBPTGS1CASP1
SCHEMBL1980286 0.79 CASP1 (0.39) RORCBRAFACACBPTGS1CASP1
SCHEMBL1982040 0.78 SYK (0.44) RORCBRAFACACBPTGS1CASP1
SCHEMBL17350072 0.75 KMT2A (0.45) RORCACACBKMT2AMEN1FFAR1
SCHEMBL17354614 0.75 RXRA (0.48) RORCPTGS1KMT2AMEN1ALDH1A1
SCHEMBL17350074 0.75 GAA (0.49) ACACBKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2017-03-09 US disclosed
EP-2509961-B1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LTD (GB) 2016-03-09 EP disclosed
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2016-03-03 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885
US-20170065585-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885
US-20160058737-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 RORC 3264/4885BRAF 2139/4885ACACB 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.